iQur is developing a novel vaccine delivery system called tandem core®. This platform technology is capable of delivering two antigens simultaneously in the highly immunogenic context of hepatitis B virus core protein. These proteins readily form virus like particles (VLP) which are both safe and well established as optimal vaccine vectors. The company’s lead product is Hepatacore®, which is a unique combined hepatitis A and B vaccine encompassed in a single recombinant protein